DRL is one of the several companies that have been facing heat in its key US market.
According to the US FDA guidelines, a recall under Class-III classification would mean the use of such drug may not cause adverse health consequences. (Photo: AFP)
Hyderabad: Dr. Reddy’s Laboratories on Thursday posted a 29 per cent drop in net profit in third quarter of fiscal 2018, owing to lower sale realisation in generics and higher tax adjustments in the US.
In Q3 FY18, the drug maker reported a profit Rs 334 crore compared to Rs 470 crore in the yearago period, a decline of 29 per cent. The revenue, however, has risen by a marginal three per cent in the period under consideration compared to the yearago quarter.
DRL is one of the several companies that have been facing heat in its key US market. As natural fallout, the company has slashed its expenditure on R&D by six per cent, while increasing its spending on selling, general and administrative expenses by the same per cent.
Next Story
